Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine and Bifidobacterium in Prediabetes
NCT02082756Phase 3Withdrawn
- Sponsor
- Xijing Hospital
- Start
- Nov 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of berberine and Golden Bifid in prediabetes (3 arms), sponsored by Xijing Hospital. Primary endpoint: Change in 2-hour postprandial blood glucose at 12 weeks. Planned start Nov 2015; status: withdrawn.
02
Drugs
berberineGolden Bifid
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT02082756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082756.